EUVIMEDEUVIMED entdecken
Crossref

Abstract 6330: Single-Dose AAV9-051 MYBPC3 Gene Therapy with Long-Term Assessment in Hypertrophic Cardiomyopathy

yang tao, Yu Xie, Ding Fusen, Yang Haitao, Qingwei Li, Qing Xie, Shuang Luo, Xiao Ke

Circulation · 02.11.2026 · 154 (Suppl_1)

DOI: 10.1161/circ.154.suppl_1.6330 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von yang tao und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Background: Hypertrophic cardiomyopathy (HCM) caused by loss-of-function variants in cardiac myosin-binding protein C (MYBPC3) remains a major inherited cause of sudden cardiac death. Available therapies improve symptoms but do not restore MYBPC3 expression. A single-dose gene replacement approach may address this disease mechanism. Research Questions/Hypothesis: We hypothesized that structure-guided engineering of an adeno-associated virus 9-derived capsid, AAV9-051, would improve cardiac delivery and enable durable MYBPC3 rescue after one systemic administration. Methods/Approach: AAV9-051 cardiac tropism was compared with parental AAV9 in C57BL/6 mice and juvenile rhesus macaques by whole-organ fluorescence imaging, vector genome quantification, and immunofluorescence reporter profiling. Therapeutic efficacy was tested in homozygous Mybpc3 knockout mice after intravenous AAV9-051-MYBPC3 at postnatal day 14 (3 x 10^13 vector genomes/kg). Echocardiography was performed longitudinally through 52 weeks; terminal analyses included heart weight morphometry, histopathology, and molecular profiling. Results/Data: Compared with AAV9, AAV9-051 produced stronger cardiac fluorescence and higher myocardial vector genome copies in mice. In rhesus macaques, AAV9-051 achieved broad ventricular reporter expression with approximately 10-fold higher enhanced green fluorescent protein signal than AAV9 (p

Zitieren

APA

tao, Y., Xie, Y., Fusen, D., Haitao, Y., Li, Q., Xie, Q., Luo, S., & Ke, X. (2026). Abstract 6330: Single-Dose AAV9-051 MYBPC3 Gene Therapy with Long-Term Assessment in Hypertrophic Cardiomyopathy. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.6330

Vancouver

tao Y, Xie Y, Fusen D, Haitao Y, Li Q, Xie Q, et al. Abstract 6330: Single-Dose AAV9-051 MYBPC3 Gene Therapy with Long-Term Assessment in Hypertrophic Cardiomyopathy. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.6330

BibTeX
@article{tao2026,
  author = {tao, yang and Xie, Yu and Fusen, Ding and Haitao, Yang and Li, Qingwei and Xie, Qing and Luo, Shuang and Ke, Xiao},
  title = {Abstract 6330: Single-Dose AAV9-051 MYBPC3 Gene Therapy with Long-Term Assessment in Hypertrophic Cardiomyopathy},
  journal = {Circulation},
  year = {2026},
  volume = {154},
  number = {Suppl_1},
  doi = {10.1161/circ.154.suppl_1.6330}
}
Kostenlos starten →